These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 9341157)
1. Transforming growth factor beta peptide antagonists and their conversion to partial agonists. Huang SS; Liu Q; Johnson FE; Konish Y; Huang JS J Biol Chem; 1997 Oct; 272(43):27155-9. PubMed ID: 9341157 [TBL] [Abstract][Full Text] [Related]
2. An active site of transforming growth factor-beta(1) for growth inhibition and stimulation. Huang SS; Zhou M; Johnson FE; Shieh HS; Huang JS J Biol Chem; 1999 Sep; 274(39):27754-8. PubMed ID: 10488119 [TBL] [Abstract][Full Text] [Related]
12. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. Leal SM; Liu Q; Huang SS; Huang JS J Biol Chem; 1997 Aug; 272(33):20572-6. PubMed ID: 9252371 [TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. Glaser KB; Li J; Aakre ME; Morgan DW; Sheppard G; Stewart KD; Pollock J; Lee P; O'Connor CZ; Anderson SN; Mussatto DJ; Wegner CW; Moses HL Mol Cancer Ther; 2002 Aug; 1(10):759-68. PubMed ID: 12492108 [TBL] [Abstract][Full Text] [Related]
14. Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. McCaffrey TA; Consigli S; Du B; Falcone DJ; Sanborn TA; Spokojny AM; Bush HL J Clin Invest; 1995 Dec; 96(6):2667-75. PubMed ID: 8675633 [TBL] [Abstract][Full Text] [Related]
15. Opposite and independent actions of cyclic AMP and transforming growth factor beta in the regulation of type 1 plasminogen activator inhibitor expression. Thalacker FW; Nilsen-Hamilton M Biochem J; 1992 Nov; 287 ( Pt 3)(Pt 3):855-62. PubMed ID: 1332686 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755 [TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor binding protein-2 mediates the inhibition of DNA synthesis by transforming growth factor-beta in mink lung epithelial cells. Dong F; Wu HB; Hong J; Rechler MM J Cell Physiol; 2002 Jan; 190(1):63-73. PubMed ID: 11807812 [TBL] [Abstract][Full Text] [Related]
19. Colon cancer cells that are not growth inhibited by TGF-beta lack functional type I and type II TGF-beta receptors. MacKay SL; Yaswen LR; Tarnuzzer RW; Moldawer LL; Bland KI; Copeland EM; Schultz GS Ann Surg; 1995 Jun; 221(6):767-76; discussion 776-7. PubMed ID: 7794080 [TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta-1 and beta-2 in human tear fluid. Gupta A; Monroy D; Ji Z; Yoshino K; Huang A; Pflugfelder SC Curr Eye Res; 1996 Jun; 15(6):605-14. PubMed ID: 8670763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]